Embodiments of the present invention provide a method of treating a stricture in a nonvascular body lumen such as urethral strictures, benign prostatic hyperplasia (BPH) strictures, ureteral strictures, esophageal strictures, sinus strictures, and biliary tract strictures. Embodiments of the present invention provide a method for treating at least one of benign prostatic hyperplasia (BPH), prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). The method can include delivering, for example, via drug coated balloon catheters, anti-inflammatory and anti-proliferative drugs (e.g., rapamycin, paclitaxel, and their analogues) and one or more additives.

Embodiments of the present invention provide a method of treating a stricture in a nonvascular body lumen such as urethral strictures, benign prostatic hyperplasia (BPH) strictures, ureteral strictures, esophageal strictures, sinus strictures, and biliary tract strictures. Embodiments of the present invention provide a method for treating at least one of benign prostatic hyperplasia (BPH), prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). The method can include delivering, for example, via drug coated balloon catheters, anti-inflammatory and anti-proliferative drugs (e.g., rapamycin, paclitaxel, and their analogues) and one or more additives.

Urinary catheters and methods for preventing bacterial infections.

Urinary catheters and methods for preventing bacterial infections.

It is provided a composition comprising phytic acid or a pharmaceutically acceptable salt thereof, for use in reducing or preventing microorganisms' proliferation and/or encrustations caused by a urinary tract device implanted in a subject, thereby preventing or treating clinical complications related to microorganisms' proliferation and/or encrustations. The composition can further comprise a urine acidifier such as methionine, a crystallization inhibitor such as theobromine and/or other agents.

It is provided a composition comprising phytic acid or a pharmaceutically acceptable salt thereof, for use in reducing or preventing microorganisms' proliferation and/or encrustations caused by a urinary tract device implanted in a subject, thereby preventing or treating clinical complications related to microorganisms' proliferation and/or encrustations. The composition can further comprise a urine acidifier such as methionine, a crystallization inhibitor such as theobromine and/or other agents.

The invention relates to a balloon catheter (1) to be introduced into the blood vessel system of the human or animal body, said catheter having a longitudinally extending shaft (2), with the balloon catheter (1) comprising a distal portion (A) in which a balloon (3) is arranged that is expandable by the supply of a fluid through a lumen (9) extending through the shaft (2), with the distal tip (8) of the balloon catheter (1) being provided with a coating consisting of a hydrogel (7). The invention provides a balloon catheter (1) capable of easily passing through constricted areas in blood vessels.

Reusable intermittent catheter products comprising a hygienic catheter including photoactive titanium dioxide.

Reusable intermittent catheter products comprising a hygienic catheter including photoactive titanium dioxide.

The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a drug coating layer that primarily uses therapeutic agents alone for improving the quality of treatments in which drug coated balloons are utilized. Particular aspects may be directed to drug coated balloon having an outer surface, and a drug coating layer on the outer surface of the balloon. The drug coating layer includes at least one therapeutic agent and is substantially free of excipients.